Deferasirox Derivatives: Ligands for the Lanthanide Series

9Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Deferasirox is an FDA-approved iron chelator used in the treatment of iron toxicity. In this work, we report the use of several deferasirox derivatives as lanthanide chelators. Solid-state structural studies of three representative trivalent lanthanide cations, La(III), Eu(III), and Lu(III), revealed the formation of 2:2 complexes in the solid state. A 1:1 stoichiometry dominates in DMSO solution, with Ka values of 472 ± 14, 477 ± 11, and 496 ± 15 M-1 being obtained in the case of these three cations, respectively. Under the conditions of competitive precipitation in the presence of triethylamine, high selectivity (up to 80%) for lutetium(III) was observed in competition with La(III), Ce(III), and Eu(III). Theoretical calculations provided support for the observed selective crystallization.

Cite

CITATION STYLE

APA

Mangel, D. N., Juarez, G. J., Carpenter, S. H., Steinbrueck, A., Lynch, V. M., Yang, J., … Sessler, J. L. (2023). Deferasirox Derivatives: Ligands for the Lanthanide Series. Journal of the American Chemical Society, 145(40), 22206–22212. https://doi.org/10.1021/jacs.3c08375

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free